Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. April 2026 16:30 ET | Quelle: Asgard Therapeutics

Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy

Asgard Therapeutics to present advanced preclinical data on its lead asset AT-108, a first-in-class, off-the-shelf cancer immunotherapy, at ASGCT 2026
17. April 2026 15:00 ET | Quelle: Asgard Therapeutics

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

Asgard Therapeutics to present a poster on its lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026.
14. April 2026 03:30 ET | Quelle: Asgard Therapeutics

Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development

Asgard Therapeutics announces the appointment of experienced medical oncologist, Professor Dr. Wolfram Brugger, as Chief Medical Officer.